In 2009, the global Osteoporosis drug market was worth USD 6.8 billion, with Bisphosphonate class of drugs leading the market. In the overall Bisphosphonate, ibandronate (Bonviva/Boniva; Roche) and zoledronate (Aclasta/Zometa; Novartis) accounted largest share in class, respectively, and showed an average sales growth rate of about of 20% in the past 2 years.

Amgen’s Denosumab is the recent entrant tthe Osteoporosis treatment market, following its approval from the U.S. and European Union (alsapproved for bone loss associated with prostate cancer). Denosumab is expected tcompete directly with the Bisphosphonate drug class. However, initial uptake of Denosumab is likely tbe as second-line therapy, mostly in patients whare intolerant tBisphosphonate. In addition tthe treatment of Osteoporosis, there is substantial potential for Denosumab for treating bone loss in patients with cancer. Denosumab market is expected treach USD 3.8 billion in 2015.

Our research indicates that the Osteoporosis drug pipeline is going strong with various phases of clinical development. Phase III has first-in-class products such as odanacatib, which possess a novel mechanism of action tcombat Osteoporosis. Aprela is another drug in the stage of development.

The Chinese Osteoporosis drug market is expected tgrow at a CAGR of 13.5% from 2010 t2015. Increased prevalence of Osteoporosis among Chinese female population is the principal growth driver of the Osteoporosis drug market. The other key growth drivers for Chinese Osteoporosis market include increasing elderly aged population, rising living standards of the Chinese people and increasing awareness and bone health education.

Geographical analysis of Chinese Osteoporosis drug market shows that there is a huge growth potential for Osteoporosis drug in many cities including Shanghai, Beijing, Guangzhou, and Hangzhou.

Tgain a competitive advantage, market players should develop cost-competitive drugs with easy dosage pattern, which promote bone building effectively. Large numbers of patients are unable tcomply with the strict dosage schedule of traditional Osteoporosis drugs. Further research and development can address the unmet need by coming up with drugs that have a convenient dosage schedule with better efficacy and safety compared ttraditional treatment of Osteoporosis.
 
After 2012, the Parathyroid Hormone and SERM Osteoporosis drug class market is expected tdecline because of anticipated growth of Prolia (Denosumab), which will largely affect other drugs’ market share.

Scope and Overview
The objective of the study on “Global and China Osteoporosis Drug Market Analysis and Forecast (2009 – 2015)” is tgain detailed market insights for key Osteoporosis drugs market segments. The market is analyzed on the basis of growth trends, ongoing developments, market penetration and revenue share. The report alscovers the strategies followed by “Osteoporosis Drugs Market” players.

Segmentation & Analysis
The report segments and analyzes the “Osteoporosis Drugs Market” on the basis of following sub-categories:

Geographic Markets

• Global
• China

By Segment

• Bisphosphonate Drugs
• SERM Drugs
• Parathyroid Hormone Drugs
• Calcitonin Drugs
• Denosumab Drugs

This section provides in-depth analysis of Osteoporosis Drugs Market size and growth forecast for each drug category, driving factors and challenges prevailing in the overall and at the micrmarket levels, and opportunities and future outlook for all the levels.

Table Of Content

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 CHINA OSTEOPOROSIS MARKET ANALYSIS, 2009 – 2015
2.1 MARKET OVERVIEW
2.2 50+ CHINESE POPULATION GROWTH TREND 2007 - 2050
2.3 CHINA POPULATION AGE STRUCTURE, 2010
2.4 CHINESE POPULATION WITH OSTEOPOROSIS, 2008 - 2050 (MILLION)
2.5 DRIVING FACTOR ANALYSIS OF CHINA OSTEOPOROSIS MARKET
2.5.1 BARGAINING POWER OF CUSTOMERS: MEDIUM/HIGH
2.5.2 BARGAINING POWER OF SUPPLIERS: LOW
2.5.3 THREAT OF SUBSTITUTE PRODUCTS: MEDIUM
2.5.4 THREAT OF ENTRY OF NEW COMPETITORS: LOW
2.5.5 INTENSITY OF COMPETITIVE RIVALRY: HIGH
2.6 APPROVED OSTEOPOROSIS TREATMENT LANDSCAPE
2.7 COMPETITIVE STRATEGIES

CHAPTER 3 CHINA OSTEOPOROSIS DRUGS MARKET
3.1 MARKET OVERVIEW
3.2 CHINESE OSTEOPOROSIS MARKET ESTIMATE & FORECAST, 2009 - 2015
3.3 DRIVERS
3.3.1 INCREASING AWARENESS OF OSTEOPOROSIS AMONG PATIENTS AS WELL AS  PHYSICIANS
3.3.2 IMPROVEMENT IN THE RATE OF DIAGNOSIS
3.3.3 BABY BOOMER GENERATION AND INCREASED LIFE EXPECTANCY
3.3.4 HEREDITARY EFFECT AND SEDENTARY LIFESTYLE
3.3.5 SMOKING AND ALCOHOLISM
3.4 RESTRAINTS AND OPPORTUNITIES
3.4.1 REIMBURSEMENT POLICIES
3.4.2 PATIENT AND PHYSICIAN EDUCATION
3.4.3 SIGNIFICANT CLINICAL UNMET NEEDS
3.5 BISPHOSPHONATE DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
3.6 SERM DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
3.7 PARATHYROID HORMONE DRUGS MARKET ANALYSIS & FORECAST, 2010 - 2015
3.8 CALCITONIN DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
3.9 DENOSUMAB DRUGS MARKET ANALYSIS: NOT COMMERCIALIZED

CHAPTER 4 GLOBAL OSTEOPOROSIS DRUGS MARKET ANALYSIS AND FORECAST, 2009 – 2015
4.1 MARKET OVERVIEW
4.2 GLOBAL OSTEOPOROSIS MARKET ESTIMATE & FORECAST, 2009 – 2015
4.3 GLOBAL BISPHOSPHONATE DRUGS MARKET ANALYSIS & FORECAST,
2009 – 2015
4.4 GLOBAL SERM DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
4.5 GLOBAL PARATHYROID HORMONE DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
4.6 GLOBAL CALCITONIN DRUGS MARKET ANALYSIS & FORECAST, 2009 – 2015
4.7 GLOBAL DENOSUMAB DRUGS MARKET ANALYSIS & FORECAST, 2010 – 2015
4.8 PIPELINE DRUGS IN OSTEOPOROSIS MARKET ANALYSIS
4.8.1 ODANACATIB (MK 0822)
4.8.2 APRELA (BAZEDOXIFENE)

CHAPTER 5 RECOMMENDATION

List of Tables

TABLE 1 APPROVED OSTEOPOROSIS TREATMENT LANDSCAPE

List of Figures

FIG. 1 50+ CHINESE POPULATION GROWTH TRENDS 2007 – 2050, (MILLION)
FIG. 2 CHINA POPULATION AGE STRUCTURE, 2010
FIG. 3 CHINESE POPULATION WITH OSTEOPOROSIS, 2008 - 2050 (MILLION)
FIG. 4 CHINESE OSTEOPOROSIS MARKET ESTIMATE & FORECAST, 2009 – 2015
(USD MILLION)
FIG. 5 CHINA BISPHOSPHONATE DRUGS MARKET ESTIMATE & FORECAST,
2009 – 2015 (USD MILLION)
FIG. 6 CHINA SERM DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015
(USD MILLION)
FIG. 7 CHINA PARATHYROID HORMONE DRUGS MARKET ESTIMATE & FORECAST, 2010 – 2015 (USD MILLION)
FIG. 8 CHINA CALCITONIN DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015 (USD MILLION)
FIG. 9 GLOBAL OSTEOPOROSIS MARKET ESTIMATE & FORECAST, 2009 – 2015
(USD MILLION)
FIG. 10 GLOBAL BISPHOSPHONATE DRUGS MARKET ESTIMATE & FORECAST,
2009 – 2015 (USD MILLION)
FIG. 11 GLOBAL SERM DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015
(USD MILLION)
FIG. 12 GLOBAL PARATHYROID HORMONE DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015 (USD MILLION)
FIG. 13 GLOBAL CALCITONIN DRUGS MARKET ESTIMATE & FORECAST, 2009 – 2015 (USD MILLION)
FIG. 14 GLOBAL DENOSUMAB DRUGS MARKET ESTIMATE & FORECAST, 2010 – 2015 (USD MILLION)